An interventional study of Contingency Management in Methamphetamine-dependence, Rectal Gonorrhea and Rectal Chlamydia, sponsored by University of California, Los Angeles. Completed at 1 site in United States. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Prevention
This clinical trial aims to investigate the effects of a decline in methamphetamine use on rectal inflammatory cytokine levels, substance use contexts, and HIV/STI risk behavior. This clinical trial also seeks to evaluate joint effects of methamphetamine use and rectal gonorrhea/chlamydia infection on rectal inflammatory cytokine levels. The proposed trial will consist of 40 MSM, half with rectal gonorrhea/chlamydia infection at enrollment (n=20), with methamphetamine use disorder that will receive contingency management for methamphetamine reduction. Following baseline measurement, participants will be observed over the course of 8 weeks, where participants will complete behavioral surveys, provide urine for drug testing, and rectal samples for measurement of rectal inflammatory cytokine levels.
University of California, Los Angeles is the lead sponsor of 1,142 studies on the registry; 192 are open to participants now.
Of its 91 completed or terminated interventional studies of FDA-regulated products, 66 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
All enrolled participants will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.
Behavioral: Contingency Management
Contingency management intervention with incentives tied to provision of urine samples with no detectable levels of methamphetamine (MA).
Methamphetamine Abstinence
Percentage of visits in which there are no detectable methamphetamine metabolites in participant urine samples
Time frame: 8 weeks
Rectal Inflammation
Rectal concentrations of IL-6 (pg/mL)
Time frame: 8 weeks
| Milestone | Contingency Management |
|---|---|
| Started | 59 |
| Completed | 30 |
| Not completed | 29 |
Percentage of visits in which there are no detectable methamphetamine metabolites in participant urine samples
| Visits | Contingency Management |
|---|---|
| Methamphetamine Abstinence | 41 |
Rectal concentrations of IL-6 (pg/mL)
| pg/ml | Contingency Management |
|---|---|
| Rectal Inflammation | 1.27 (0.07 to 3462.39) |
Collected over From enrollment until end of follow-up, up to 8 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Contingency Management | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
Participants who were lost to follow-up were not included in analyses
| Age, Categorical(Participants) | Contingency Management |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 30 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Contingency Management |
|---|---|
| Female | 0 |
| Male | 30 |
| Race (NIH/OMB)(Participants) | Contingency Management |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 10 |
| White | 8 |
| More than one race | 8 |
| Unknown or Not Reported | 4 |
| Ethnicity (NIH/OMB)(Participants) | Contingency Management |
|---|---|
| Hispanic or Latino | 13 |
| Not Hispanic or Latino | 15 |
| Unknown or Not Reported | 2 |
| STI at baseline(Participants) | Contingency Management |
|---|---|
| Count of participants | 7 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: Undecided
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Los Angeles